Leiden, Netherlands, May 22, 2026
Pharming Group N.V. has announced that the European Commission (EC) has granted Marketing Authorization for Joenja® (leniolisib), making it the first approved treatment in the European Union for Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS), a rare and progressive primary immunodeficiency disorder. The approval marks a major milestone for rare disease treatment in Europe and strengthens Pharming’s expanding global commercial strategy in immunology and precision medicine.
The approval covers both adult and pediatric patients aged 12 years and older and follows earlier regulatory clearances in the United States, United Kingdom, Japan, Australia, and Israel. Pharming confirmed that the first European commercial launch is expected in Germany during Q3 2026, with additional European rollouts planned after reimbursement discussions are finalized across different markets.
Joenja Becomes Europe’s First Approved APDS Therapy
Joenja® (leniolisib) is an oral selective PI3K delta inhibitor specifically designed to target the underlying biological cause of APDS, a rare genetic immune disorder first characterized in 2013. The disease is caused by mutations in the PIK3CD or PIK3R1 genes, leading to hyperactivation of the PI3Kδ pathway, which disrupts immune cell development and function. Patients living with APDS often experience severe recurrent infections, autoimmune complications, enlarged lymph nodes, enteropathy, and long-term immune dysregulation.
The European Commission approval was supported by results from a multinational, randomized, triple-blind, placebo-controlled Phase II/III clinical trial involving patients aged 12 years and older. The study demonstrated statistically significant improvements in markers associated with immune dysregulation and immunodeficiency. Regulatory submissions also included long-term open-label extension data from patients treated with leniolisib for a median duration of approximately three years, supporting the therapy’s long-term safety and tolerability profile.
Advertisement
Healthcare experts have described the approval as a major advancement in the management of APDS because therapeutic options for the condition were previously extremely limited. Researchers noted that the treatment’s targeted mechanism directly addresses the disease’s underlying pathophysiology instead of only managing symptoms, potentially changing long-term disease management strategies for affected patients across Europe.
Rare Disease Expansion Strengthens Pharming’s Global Strategy
Pharming stated that the EC approval reinforces its commitment to addressing unmet needs in rare and life-threatening diseases through innovative therapies and precision medicine approaches. The company believes Joenja has the potential to significantly improve quality of life for APDS patients and reduce complications caused by delayed diagnosis and chronic immune dysfunction.
APDS is estimated to affect approximately 1 to 2 individuals per million worldwide, and studies suggest patients frequently experience an average diagnostic delay of nearly seven years due to the complexity and rarity of symptoms. Experts warn that delayed diagnosis may result in irreversible lung damage, lymphoma risk, and long-term immune complications. The availability of the first approved targeted therapy in Europe is therefore expected to improve disease awareness, diagnostic pathways, and patient outcomes across the region.
In addition to APDS, Pharming continues evaluating leniolisib in other primary immunodeficiencies with immune dysregulation through ongoing Phase II clinical studies. The company is also pursuing additional regulatory approvals in multiple international markets as part of its broader rare disease expansion strategy.
The approval further strengthens the growing importance of precision immunology and targeted therapies within the global pharmaceutical industry, particularly in rare diseases where treatment options remain limited and unmet clinical need remains high.
Source: Pharming press release
